T. Abell, C. G. Quilici, J. Pankert, M. Deharo, P. Bonnet et al., Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome, Int J Cardiol, vol.168, issue.3, pp.2988-2997, 2013.

A. Abernethy, G. Raman, E. Balk, J. Hammond, L. Orlando et al., Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications, Annals of Internal Medicine, vol.150, issue.5, pp.336-379, 2009.
DOI : 10.7326/0003-4819-150-5-200903030-00107

G. Addolorato, F. Caputo, E. Capristo, M. Domenicali, M. Bernardi et al., BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY, Alcohol and Alcoholism, vol.37, issue.5, pp.504-512, 2002.
DOI : 10.1093/alcalc/37.5.504

G. Addolorato, L. Leggio, A. Ferrulli, S. Cardone, L. Vonghia et al., Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study, The Lancet, vol.370, issue.9603, pp.1915-1937, 2007.
DOI : 10.1016/S0140-6736(07)61814-5

S. Aisenbrey, F. Ziemssen, M. Völker, F. Gelisken, P. Szurman et al., Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration, Graefe's Archive for Clinical and Experimental Ophthalmology, vol.25, issue.7, pp.941-949, 2006.
DOI : 10.1001/archopht.117.10.1329

E. Van-allen, T. Miyake, N. Gunn, C. Behler, and J. Kohlwes, Off-Label Use of Rituximab in a Multipayer Insurance System, Journal of Oncology Practice, vol.7, issue.2, pp.76-85, 2011.
DOI : 10.1200/JOP.2010.000042

D. Allison, R. El-azhary, S. Calobrisi, and C. Dicken, Pityriasis rubra pilaris in children, Journal of the American Academy of Dermatology, vol.47, issue.3, pp.386-395, 2002.
DOI : 10.1067/mjd.2002.124619

O. Ameisen, D. Beaurepaire, and R. , Suppression de la d??pendance ?? l???alcool et de la consommation d???alcool par le baclof??ne ?? haute dose??: un essai en ouvert, Annales M??dico-psychologiques, revue psychiatrique, vol.168, issue.2, pp.159-62, 2010.
DOI : 10.1016/j.amp.2009.12.008

L. Andreoli, M. Gaudoneix, P. Beauverie, and R. De-beaurepaire, Prescriptions hors autorisation de mise sur le march?? en psychiatrie publique hospitali??re, Th??rapie, vol.68, issue.6, pp.347-59, 2013.
DOI : 10.2515/therapie/2013054

A. and R. Temporaire, Disponible sur: http://ansm.sante.fr/var/ansm_site/storage/original/application/2976e3c2bb5c0e5265 a35955df5e8de0.pdf ANSM Avastin 25mg/ml (bevacizumab) : Avis favorable de la commission bénéfice/risque pour une recommandation temporaire d'utilisation (RTU), 2014.

N. Asai, Y. Ohkuni, A. Komatsu, R. Matsunuma, K. Nakashima et al., Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE, J Bras Pneumol Publicaça? o Of Soc Bras Pneumol E Tisilogia, vol.37, issue.4, pp.567-70, 2011.

M. Auffret, R. B. Deheul, S. Lecomte, L. Cottencin, O. Bordet et al., CAMTEA, un dispositif original de prescription encadr??e hors-AMM de baclof??ne dans le Nord???Pas-de-Calais??: quels r??les pour le pharmacien???, Annales Pharmaceutiques Fran??aises, vol.72, issue.1, pp.28-32, 2013.
DOI : 10.1016/j.pharma.2013.09.005

M. Auffret, R. B. Deheul, S. Lecomte, L. Cottencin, O. Bordet et al., CAMTEA, un dispositif original de prescription encadr??e hors-AMM de baclof??ne dans le Nord???Pas-de-Calais??: quels r??les pour le pharmacien???, Annales Pharmaceutiques Fran??aises, vol.72, issue.1, pp.28-32, 2014.
DOI : 10.1016/j.pharma.2013.09.005

M. Auffret, R. B. Deheul, S. Loche, V. Hennaux, C. Cottencin et al., Severe Tinnitus Induced by Off-Label Baclofen, Annals of Pharmacotherapy, vol.18, issue.5, pp.656-665, 2014.
DOI : 10.1177/000348949510400511

R. Avery, D. Pieramici, M. Rabena, A. Castellarin, M. Nasir et al., Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration, Ophthalmology, vol.113, issue.3, pp.363-72, 2006.
DOI : 10.1016/j.ophtha.2005.11.019

C. Azoulay and E. Daraï, Traitement médicamenteux de l'endométriose (adénomyose exclue)

J. Bardon, J. Fink, J. De-montblanc, J. Bergmann, B. Sarrut et al., Utilisation hors AMM du facteur VII activ?? recombinant (Novoseven??) ?? l???AP???HP en 2010, Annales Fran??aises d'Anesth??sie et de R??animation, vol.32, issue.10, pp.659-64, 2010.
DOI : 10.1016/j.annfar.2013.05.007

V. Bargoin, Les sociétés savantes américaines laissent une place à l'aspirine en prévention primaire chez les diabétiques, p.3104531

J. Barletta, I. Lat, S. Micek, H. Cohen, K. Olsen et al., Off-Label Use of Gastrointestinal Medications in the Intensive Care Unit, Journal of Intensive Care Medicine, vol.321, issue.16, 2013.
DOI : 10.1345/aph.1L123

S. Barnett, M. Kramer, C. Casat, K. Connor, and J. Davidson, Efficacy of olanzapine in social anxiety disorder: a pilot study, Journal of Psychopharmacology, vol.1, issue.17, pp.365-373, 2002.
DOI : 10.1192/bjp.161.3.353

Z. Bashshur, A. Bazarbachi, A. Schakal, Z. Haddad, E. Haibi et al., Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration, American Journal of Ophthalmology, vol.142, issue.1, pp.1-9, 2006.
DOI : 10.1016/j.ajo.2006.02.037

M. Bauer, A. Lee, M. Li, L. Bajor, A. Rasmusson et al., Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates, Pharmacoepidemiology and Drug Safety, vol.28, issue.5, pp.77-86, 2014.
DOI : 10.1377/hlthaff.28.5.w782

R. Beaurepaire and . De, Vérités et mensonges sur le baclofène [Internet] Albin Michel; 2013. Disponible sur: http://books.google.fr/books?, pp.9-1984

E. Beccastrini, D. Squatrito, G. Emmi, P. Fabbri, and E. L. , Alopecia areata universalis during offlabel treatment with Infliximab in a patient with Behçet disease, Dermatol Online J, vol.16, issue.9, p.15, 2010.

D. Bégué, La prescription de médicaments hors AMM, Médecine Droit, issue.60, pp.85-94, 2003.

H. Bei, L. Ross, J. Neuhaus, D. Knopman, J. Kramer et al., Off-Label Medication Use in Frontotemporal Dementia, American Journal of Alzheimer's Disease & Other Dementiasr, vol.25, issue.2, pp.128-161, 2010.
DOI : 10.1212/01.WNL.0000113729.77161.C9

D. Berardis, G. Sacco, M. Strippoli, G. Pellegrini, F. Graziano et al., Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials, BMJ, vol.339, issue.nov06 1, 2009.
DOI : 10.1136/bmj.b4531

D. Berchery, H. Roussel, R. Bourrel, and V. Sciortino, Utilisation des h??parines en m??decine de ville : donn??es de l???Assurance Maladie de Midi-Pyr??n??es, Th??rapie, vol.58, issue.5, pp.431-438, 2003.
DOI : 10.2515/therapie:2003070

S. Berdot, E. Papy, C. Rioux, S. Diamantis, R. Ruimy et al., Bilan de l'utilisation de la moxifloxacine dans le

B. Polak, M. Behar-cohen, and F. , D??g??n??rescence maculaire li??e ?? l?????ge exsudative??: efficacit?? et limites des diff??rents traitements, Journal Fran??ais d'Ophtalmologie, vol.31, issue.5, pp.537-56, 2008.
DOI : 10.1016/S0181-5512(08)72475-6

S. Berthet, B. Charpiat, and J. Mabrut, Facteurs de risque de l???utilisation de l?????rythromycine comme agent prokin??tique, Journal de Chirurgie Visc??rale, vol.147, issue.2, pp.100-105, 2010.
DOI : 10.1016/j.jchirv.2010.06.001

G. Besozzi, A. Ferrara, E. Epifani, D. Intini, M. Apruzzese et al., Acute stroke after intravitreal bevacizumab to treat choroidal neovascularization due to angioid streaks in pseudoxanthoma elasticum, International Ophthalmology, vol.370, issue.9583, pp.181-184, 2013.
DOI : 10.1016/S0140-6736(07)61104-0

G. Beucher, P. Dolley, G. Carles, F. Salaun, I. Asselin et al., Misoprostol??: utilisation hors AMM au premier trimestre de la grossesse (fausses couches spontan??es, interruptions m??dicales et volontaires de grossesse), Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.123-168, 2014.
DOI : 10.1016/j.jgyn.2013.11.007

G. Beucher, P. Dolley, G. Carles, F. Salaun, I. Asselin et al., Misoprostol??: utilisation hors AMM au premier trimestre de la grossesse (fausses couches spontan??es, interruptions m??dicales et volontaires de grossesse), Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.45-123, 2014.
DOI : 10.1016/j.jgyn.2013.11.007

J. Biga, Pour un bon usage des IPP

C. Binot, La dégénérescence maculaire liée à l'âge et sa prévention: l'essor de la micronutrition

E. Bollinger, Vers un afflux d'ordonnance du baclofène, Monit Pharm, issue.3024, 2014.

H. Bonnemain and B. Bonnemain, Les relations entre l'industrie pharmaceutique et les pouvoirs publics en France au cours des deux derniers si??cles : de la libert?? ?? la libert?? surveill??e, Revue d'histoire de la pharmacie, vol.90, issue.334, pp.90-239, 2002.
DOI : 10.3406/pharm.2002.5360

URL : http://www.persee.fr/docAsPDF/pharm_0035-2349_2002_num_90_334_5360.pdf

O. Bon, Low-dose Trazodone Effective in Insomnia, Pharmacopsychiatry, vol.38, issue.5, pp.226-226, 2005.
DOI : 10.1055/s-2005-873160

L. Bossini, I. Casolaro, D. Koukouna, F. Cecchini, and A. Fagiolini, Off-label uses of trazodone: a review, Expert Opinion on Pharmacotherapy, vol.42, issue.2, pp.1707-1724, 2012.
DOI : 10.1097/00004714-199710000-00004

G. Boutet, Traitement des bouff??es de chaleur apr??s cancer du sein, Gyn??cologie Obst??trique & Fertilit??, vol.40, issue.4, pp.241-54, 2012.
DOI : 10.1016/j.gyobfe.2012.02.015

P. Bret, M. Heil, E. Queuille, and M. Bret, Enqu??te des prescriptions de risp??ridone injectable ?? lib??ration prolong??e dans neuf centres hospitaliers du r??seau PIC, L'Enc??phale, vol.37, pp.58-65, 2011.
DOI : 10.1016/j.encep.2010.04.001

L. Breuer, C. Blinzler, H. Huttner, I. Kiphuth, S. Schwab et al., Off-Label Thrombolysis for Acute Ischemic Stroke: Rate, Clinical Outcome and Safety Are Influenced by the Definition of ???Minor Stroke???, Cerebrovascular Diseases, vol.341, issue.2, pp.177-85, 2011.
DOI : 10.1136/bmj.c6046

E. Brezinski and A. Armstrong, Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy, PLoS ONE, vol.306, issue.15, p.33486, 2012.
DOI : 10.1371/journal.pone.0033486.s010

J. Brown, C. Farquhar, O. Lee, R. Toomath, and R. Jepson, Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne, Cochrane Database Syst Rev, issue.2, p.194, 2009.

J. Burad, P. Bhakta, and J. Sharma, Timely « off-label » use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature, Indian J Anaesth, vol.56, issue.1, pp.69-71, 2012.

S. Butterly, P. Pillans, B. Horn, R. Miles, and J. Sturtevant, Off-label use of rituximab in a tertiary Queensland hospital, Internal Medicine Journal, vol.146, issue.6, pp.443-52, 2010.
DOI : 10.7326/0003-4819-146-1-200701020-00006

. Caisse-nationale-de-l-'assurance and . Maladie, Consommation et dépenses de médicaments en Europe [Internet], Disponible sur, 2007.

C. Carette, L. Muzard, A. Radu, C. Barsamian, and M. Bretault, Traitement pharmacologique de l'obésité, Médecine Clin Endocrinol Diabète, issue.61, 2014.

L. Carlucci, D. Pomerol, M. Laguerre, D. Gimbert, E. Dautheribes et al., H??morragies intracr??niennes de l???adulte??: implication de plus en plus importante des traitements antithrombotiques???, Neurochirurgie, vol.59, issue.1, pp.17-22, 2013.
DOI : 10.1016/j.neuchi.2012.10.139

A. Carney, Efficacy of Quetiapine Off-Label Uses: Data Synthesis, Journal of Psychosocial Nursing and Mental Health Services, vol.51, issue.8, pp.11-19, 2013.
DOI : 10.3928/02793695-20130709-01

J. Carpenter, A. Storniolo, S. Johns, P. Monahan, F. Azzouz et al., Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. The Oncologist, pp.124-159, 2007.

M. Carr and B. Vickaryous, Life, limb or off-label recombinant VIIa use in the setting of limited blood assets, Blood Coagulation & Fibrinolysis, vol.24, issue.4, pp.436-444, 2013.
DOI : 10.1097/MBC.0b013e32835cc12c

. Catt-research-group, D. Martin, M. Maguire, G. Ying, J. Grunwald et al., Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, vol.364, issue.20, pp.1897-908, 2011.

M. Caussin, H. Haupais, N. Massy, I. Marie, C. Zarnitsky et al., Analyse des prescriptions de rituximab en Haute-Normandie, La Revue de M??decine Interne, vol.32, issue.S2, p.374, 2011.
DOI : 10.1016/j.revmed.2011.10.145

A. Cavailhes, B. Balme, D. Gilbert, and F. Skowron, Succ??s de l???association rituximab???cortico??des g??n??raux dans le traitement d???une ??pidermolyse bulleuse acquise r??calcitrante, Annales de Dermatologie et de V??n??r??ologie, vol.136, issue.11, pp.795-804, 2009.
DOI : 10.1016/j.annder.2009.02.007

M. Cecchi, M. Vaiani, M. Ceroti, and R. Banfi, A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma, International Journal of Clinical Pharmacy, vol.19, issue.12, pp.483-490, 2013.
DOI : 10.1016/j.jocn.2011.12.028

C. Chen, T. Wong, and W. Heriot, Intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Short-term Study, American Journal of Ophthalmology, vol.143, issue.3, pp.510-512, 2007.
DOI : 10.1016/j.ajo.2006.10.004

R. Collier, Scrutiny of Diane-35 due to potential dangers of off-label prescribing, Canadian Medical Association Journal, vol.185, issue.5, pp.217-225, 2013.
DOI : 10.1503/cmaj.109-4414

C. Combe, C. Bourne, M. Chiganne, M. Geneste, H. Hida et al., Fentanyl transmuqueux??: ??valuation pratique de son utilisation aupr??s des patients et des soignants, M??decine Palliative : Soins de Support - Accompagnement - ??thique, vol.13, issue.2, pp.77-83, 2014.
DOI : 10.1016/j.medpal.2013.10.001

D. Conde-estevez, S. Grau, J. Horcajada, and S. Luque, Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes, International Journal of Antimicrobial Agents, vol.36, issue.5, pp.471-473, 2010.
DOI : 10.1016/j.ijantimicag.2010.07.006

G. Coppa and . Glioblastomes, évènements vasculaires et bévacizumab : expérience monocentrique de l'unité de neurooncologie du CHU de Nancy

L. Courtois and P. , Rendre possible un accès plus précoce au médicament. Ann Mines, Février, pp.23-30, 2005.

D. Curcio, Off-label use of antibiotics in hospitalized patients: focus on tigecycline, Journal of Antimicrobial Chemotherapy, vol.185, issue.10, pp.1344-1350, 2009.
DOI : 10.1093/jac/dki248

D. Curcio, Off-label use of antibiotics in intensive care unit: The multidrug-resistant pathogens challenge, Journal of Critical Care, vol.26, issue.1, pp.95-101, 2011.
DOI : 10.1016/j.jcrc.2010.10.009

I. Danés, A. Agustí, A. Vallano, J. Martínez, C. Alerany et al., Available evidence and outcome of off-label use of rituximab in clinical practice, European Journal of Clinical Pharmacology, vol.297, issue.9, pp.1689-99, 2013.
DOI : 10.1001/jama.297.7.683

V. Danivas, N. Moily, R. Thimmaiah, K. Muralidharan, M. Purushotham et al., Off label use of lithium in the treatment of Huntington???s disease: A case series, Indian Journal of Psychiatry, vol.55, issue.1, pp.81-84, 2013.
DOI : 10.4103/0019-5545.105522

C. David, H. Nguyen, and G. Goldenberg, Imiquimod: a review of off-label clinical applications, J Drugs Dermatol JDD, vol.10, issue.11, pp.1300-1306, 2011.

A. Delpeuch, D. Leveque, R. L. Bergerat, and J. , Off-label use of oxaliplatin in patients with metastatic breast cancer, Anticancer Res, vol.31, issue.5, pp.1765-1772, 2011.

D. 'erme, A. Milanesi, N. Difonzo, E. Lotti, T. Gola et al., Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: A valid therapeutic option, Dermatologic Therapy, vol.127, issue.5, pp.281-283, 2012.
DOI : 10.1111/j.1365-2133.1992.tb14851.x

K. Devulapalli and H. Nasrallah, An analysis of the high psychotropic off-label use in psychiatric disorders The majority of psychiatric diagnoses have no approved drug

C. Díaz-lagares, R. Pérez-alvarez, F. García-hernández, M. Ayala-gutiérrez, J. Callejas et al., Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label, Arthritis Research & Therapy, vol.13, issue.4, p.112, 2011.
DOI : 10.1002/art.27555

C. Diaz-lagares, R. Perez-alvarez, F. Garcia-hernandez, M. Ayala-gutierrez, J. Callejas et al., Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label, Arthritis Research & Therapy, vol.13, issue.4, p.112, 2011.
DOI : 10.1002/art.27555

C. Dicken, Treatment of classic pityriasis rubra pilaris, Journal of the American Academy of Dermatology, vol.31, issue.6, pp.997-1006, 1994.
DOI : 10.1016/S0190-9622(94)70271-3

P. Donovan, J. Iedema, D. Mcleod, P. Kubler, and P. Pillans, Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland, ANZ Journal of Surgery, vol.42, issue.Suppl. 1, pp.149-54, 2013.
DOI : 10.1111/j.1445-5994.2012.02713.x

J. Douat, S. Auriol, L. Mahieu-durringer, E. Ancèle, V. Pagot-mathis et al., Utilisation du bevacizumab en injection intravitr??enne dans le traitement du glaucome n??ovasculaire. ?? propos de 20 cas, Journal Fran??ais d'Ophtalmologie, vol.32, issue.9, pp.652-63, 2009.
DOI : 10.1016/j.jfo.2009.10.001

N. Fabre, Traitement de l'algie vasculaire de la face, Rev Neurol, vol.156, pp.4-93, 2000.

F. Fajnkuchen and S. Cohen, Utilisation des anti-VEGF dans la d??g??n??rescence maculaire li??e ?? l?????ge, Journal Fran??ais d'Ophtalmologie, vol.31, issue.1, pp.94-110, 2008.
DOI : 10.1016/S0181-5512(08)70342-5

A. Fazelat and K. Lashkari, Off-label use of intravitreal triamcinolone acetonide for diabetic macular edema in a pregnant patient, Clinical Ophthalmology, vol.5, pp.439-480, 2011.
DOI : 10.2147/OPTH.S14584

M. Fornaro and M. Martino, Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report, Annals of General Psychiatry, vol.9, issue.1, p.39, 2010.
DOI : 10.1186/1744-859X-9-39

. France, Article R4127-40 [Internet] Code Santé Publique Disponible sur, 2004.

. France, Article R5121-36-1 [Internet] Code Santé Publique, Disponible sur, 2008.

. France, Article R4127-8 [Internet] Code Santé Publique 2010 Disponible sur

. France, Article L5121-9, Créé par loi n°2013-185 du 1er mars 2013 -art

. France, Article R5121-43, Créé par Décret n°2013-222 du 15 mars 2013 -art

. France, Article L5121-12-1, Modifié par loi n°2014-892 du 8 août 2014 -art, 20140203.

P. Friedland, Prescription hors AMM [Internet] Village Justice Communauté Avocats Juristes Fisc. Notaires Huissiers Paralegals, Disponible sur, pp.9-10, 2004.

C. Fukada, J. Kohler, H. Boon, Z. Austin, and M. Krahn, Prescribing Gabapentin off Label: Perspectives from Psychiatry, Pain and Neurology Specialists, Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, vol.37, issue.6, pp.280-284, 2012.
DOI : 10.1155/2007/730785

C. Fullerton, A. Busch, and R. Frank, The Rise and Fall of Gabapentin for Bipolar Disorder, Medical Care, vol.48, issue.4, pp.372-381, 2010.
DOI : 10.1097/MLR.0b013e3181ca404e

K. Furie, Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR) Ann Rheum, p.253, 2009.

I. Gabai and E. Spierings, Prophylactic Treatment of Cluster Headache with Verapamil, Headache: The Journal of Head and Face Pain, vol.29, issue.3, pp.167-175, 1989.
DOI : 10.1111/j.1526-4610.1989.hed2903167.x

S. Ganjian, A. Ourian, G. Shamtoub, J. Wu, and J. Murase, Off-label indications for imiquimod, Dermatol Online J, vol.15, issue.5, p.4, 2009.

J. Garbutt, A. Kampov-polevoy, R. Gallop, L. Kalka-juhl, and B. Flannery, Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial, Alcoholism: Clinical and Experimental Research, vol.12, issue.11, pp.1849-57, 2010.
DOI : 10.1001/archpsyc.1965.01720310065008

A. Garrigue and F. Pierre, Misoprostol??: utilisation hors AMM dans la prise en charge de l???h??morragie du post-partum, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.179-89, 2014.
DOI : 10.1016/j.jgyn.2013.11.011

C. Geffroy, E. Couffin, J. Doucet, P. Carvalho, L. Sibert et al., Prescriptions inappropriées d'héparine à dose curative en milieu hospitalier, l'information des prescripteurs diminue-t-elle les erreurs ? Presse Médicale, pp.303-314, 2002.

C. Gégu, N. Gagnon, C. Schmitt, L. Tichadou, M. Hayek-lanthois et al., Traitement par doses ??lev??es de baclof??ne ?? l???origine d???un surdosage chez un ??thylique chronique insuffisant r??nal, Th??rapie, vol.67, issue.6, pp.529-560, 2012.
DOI : 10.2515/therapie/2012070

R. Gi, T. Ilmarinen, E. Heuvel, . Van-den, L. Aaltonen et al., Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients, Eur Arch Otorhinolaryngol, vol.270, issue.5, pp.1679-87, 2013.

J. Giroux, A. Coubret, and Y. Nouaille, Le point sur les pilules estroprogestatives et le risque de thrombose veineuse, Actualit??s Pharmaceutiques, vol.52, issue.527, pp.42-47, 2013.
DOI : 10.1016/j.actpha.2013.03.020

P. Glue and C. Gale, Off-label use of quetiapine in New Zealand--a cause for concern?, N Z Med J, vol.124, pp.10-13, 1336.

G. Godet, J. Kretz, and T. Cristea, Prescription des h??parines de bas poids mol??culaire en chirurgie vasculaire : r??sultats de l'enqu??te Ephebe, Annales Fran??aises d'Anesth??sie et de R??animation, vol.24, issue.4, pp.347-54, 2005.
DOI : 10.1016/j.annfar.2005.01.011

L. Goldsmith, A. Weinrich, and J. Shupack, Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin), Journal of the American Academy of Dermatology, vol.6, issue.4, pp.710-715, 1982.
DOI : 10.1016/S0190-9622(82)70061-1

H. Gollnick, U. Blume-peytavi, E. Szabó, K. Meyer, P. Hauptmann et al., Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, vol.6, issue.7, pp.505-520, 2010.
DOI : 10.1111/j.1610-0387.2010.07345.x

. Gouvernement, Disponible sur: http://www.assemblee-nationale, 2014.

A. Grant, T. Gonzalez, M. Montgomery, V. Cardenas, and F. Kerdel, Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial, Journal of the American Academy of Dermatology, vol.62, issue.2, pp.205-222, 2010.
DOI : 10.1016/j.jaad.2009.06.050

A. Greensill, M. Yong, O. Mahony, and C. , Imiquimod use in adolescents: off-label but effective, International Journal of STD & AIDS, vol.2, issue.4, pp.297-306, 2012.
DOI : 10.1097/01.inf.0000253958.11585.d3

D. Guardia, R. B. Deheul, S. Danel, T. Bordet, R. Cottencin et al., Prescription hors-AMM de topiramate dans le trouble hyperphagique au sein du dispositif CAMTEA, Th??rapie, vol.67, issue.5, pp.480-481, 2012.
DOI : 10.2515/therapie/2012063

S. Gueho and N. Richard, Utilisation des anti-VEGF dans le traitement local de la DMLA et autres rétinopathies. ANSM

C. Halverstam and M. Lebwohl, Nonstandard and off-label therapies for psoriasis, Clinics in Dermatology, vol.26, issue.5, pp.546-53, 2008.
DOI : 10.1016/j.clindermatol.2007.10.023

B. Hamel, P. Courtet, C. Vergnes, and J. Boulenger, Prescription hospitalière de la rispéridone et de l'olanzapine: enquête et recommandations, J Pharm Clin, vol.19, issue.3, pp.187-93, 2000.

W. Hanf, J. Duntze, H. Hida, Q. Blanc, and C. Reynaud, Imputabilit?? d???une mise en jeu du pronostic vital ?? un inhibiteur sp??cifique de la thrombine, Annales Fran??aises d'Anesth??sie et de R??animation, vol.28, issue.10, pp.885-893, 2009.
DOI : 10.1016/j.annfar.2009.08.004

D. Hartung, L. Middleton, B. Mcfarland, D. Haxby, M. Mcdonagh et al., Use of Administrative Data to Identify Off-Label Use of Second-Generation Antipsychotics in a Medicaid Population, Psychiatric Services, vol.64, issue.12, pp.1236-1278, 2013.
DOI : 10.1176/appi.ps.005482012

Y. Hassani, C. Hochart, L. Hassani, S. Taillibert, K. Xuan et al., Outils de suivi et d'autoévaluation de l'irinotécan et du bévacizumab dans les glioblastomes: de la prescription à l'information du patient, Bull Cancer, vol.99, issue.5, pp.513-533, 2012.

A. Hayanga, Off-Label Use of Recombinant Factor VIIa, Annals of Internal Medicine, vol.155, issue.5, pp.337-345, 2011.
DOI : 10.7326/0003-4819-155-5-201109060-00021

P. Hebert, D. Fergusson, and M. Stanbrook, Off-label use of recombinant factor VIIa: why we need better drug monitoring, Canadian Medical Association Journal, vol.183, issue.1, pp.26-33, 2011.
DOI : 10.1503/cmaj.101842

U. Hengge, Off-label indications for topical tacrolimus, Der Hautarzt, vol.51, issue.10, pp.752-758, 2013.
DOI : 10.1016/j.jaad.2004.05.036

N. Henry, M. Rouprêt, C. Ciofu, B. Gattegno, P. Thibault et al., Prise en charge de l?????jaculation pr??matur??e chez le sujet adulte, Progr??s en Urologie, vol.18, issue.9, pp.566-575, 2008.
DOI : 10.1016/j.purol.2008.03.030

E. Hernandez-perez, H. Khawaja, and T. Alvarez, Oral Isotretinoin as Part of the Treatment of Cutaneous Aging, Dermatologic Surgery, vol.26, issue.7, pp.649-52, 2000.
DOI : 10.1046/j.1524-4725.2000.99210.x

R. Hoff and A. Braam, [Off-label prescriptions in acute psychiatry: a practice-based evaluation]. Tijdschr Voor Psychiatr, pp.233-278, 2013.

K. Ho and E. Litton, Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion, Transfusion, vol.6, issue.1, pp.1696-702, 2012.
DOI : 10.1371/journal.pone.0018987

E. Horowitz, L. Bergman, C. Ashkenazy, I. Moscona-hurvitz, H. Grinvald-fogel et al., Off-Label Use of Sodium Valproate for Schizophrenia, PLoS ONE, vol.23, issue.6, p.92573, 2014.
DOI : 10.1371/journal.pone.0092573.t006

K. Hostettler, U. Studler, M. Tamm, and M. Brutsche, Long-Term Treatment with Infliximab in Patients with Sarcoidosis, Respiration, vol.47, issue.3, pp.218-242, 2012.
DOI : 10.1093/rheumatology/kem336

M. Huret, Prophylaxie thromboembolique lors des voyages aériens long-courriers : recommandations et pratiques des médecins généralistes [Internet]. [Paris XII]: Faculté de médecine de Créteil, Disponible sur

M. Hyde, M. Hadley, P. Tristani-firouzi, D. Goldgar, and G. Bowen, A Randomized Trial of the Off-label Use of Imiquimod, 5%, Cream With vs Without Tazarotene, 0.1%, Gel for the Treatment of Lentigo Maligna, Followed by Conservative Staged Excisions, Archives of Dermatology, vol.148, issue.5, pp.592-598, 2012.
DOI : 10.1001/archdermatol.2012.270

C. Imbert, L. Martin, D. Hoang-nguyen, J. Oliary, and H. Barreteau, Inhibiteurs de la lactation??: analyse des pratiques de prescriptions, Le Pharmacien Hospitalier et Clinicien, vol.48, issue.4, pp.276-283, 2013.
DOI : 10.1016/j.phclin.2013.10.050

D. La and . Du, RÈGLEMENT (CE) No 1234, Disponible sur, 2008.

N. Kahan, D. Waitman, S. Blackman, and D. Vardy, Drug Use Evaluation of Tamoxifen Focusing on Off-Label Use in a Managed Care Population in Israel, Journal of Managed Care Pharmacy, vol.16, issue.5, pp.355-364, 2010.
DOI : 10.18553/jmcp.2010.16.5.355

P. Kamble, J. Sherer, H. Chen, and R. Aparasu, Off-Label Use of Second-Generation Antipsychotic Agents Among Elderly Nursing Home Residents, Psychiatric Services, vol.61, issue.2, pp.130-136, 2010.
DOI : 10.1176/ps.2010.61.2.130

K. Karkouti and J. Levy, A Hemorrhage of Off-Label Use, Annals of Internal Medicine, vol.155, issue.5, pp.339-379, 2011.
DOI : 10.7326/0003-4819-155-5-201109060-00023

K. Kaufman and P. Struck, Gabapentin-induced sexual dysfunction, Epilepsy & Behavior, vol.21, issue.3, pp.324-330, 2011.
DOI : 10.1016/j.yebeh.2011.04.058

K. Kaufman, P. Struck, B. Wu, and S. Wong, Off-label gabapentin masking ictal triphasic waves: Case analysis of neuropsychiatric and electrographic correlates, Epilepsy & Behavior, vol.22, issue.3, pp.606-615, 2011.
DOI : 10.1016/j.yebeh.2011.08.018

A. Kent, Off-label use of misoprostol and oxytocin, Rev Obstet Gynecol, vol.2, issue.4, pp.245-251, 2009.

A. Kesselheim, D. Darby, D. Studdert, R. Glynn, R. Levin et al., False Claims Act Prosecution Did Not Deter Off-Label Drug Use In The Case Of Neurontin, Health Affairs, vol.30, issue.12, pp.2318-2345, 2011.
DOI : 10.1377/hlthaff.2011.0370

A. Kesselheim, M. Mello, and J. Avorn, FDA Regulation of Off-label Drug Promotion Under Attack, JAMA, vol.309, issue.5
DOI : 10.1001/jama.2012.207972

G. Kim, D. Rosso, and J. , Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris, J Clin Aesthetic Dermatol, vol.5, issue.3, pp.37-50, 2012.

Z. Kmietowicz, Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine, BMJ, vol.338, issue.jan20 1, p.217, 2009.
DOI : 10.1136/bmj.b217

E. Krause, S. Malorgio, A. Kuhn, C. Schmid, M. Baumann et al., Off-label use of misoprostol for labor induction: a nation-wide survey in Switzerland, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.159, issue.2, pp.324-332, 2011.
DOI : 10.1016/j.ejogrb.2011.09.013

C. Laborde, Les traitements médicamenteux de l'endométriose génitale (en dehors de l'adénomyose) Drug treatments for genital endometriosis (excepting adenomyosis), J Gynécologie Obstétrique Biol Reprod, vol.36, issue.2, pp.201-235, 2007.

L. Lai, M. Tan, and Y. Lai, Prevalence and factors associated with off-label antidepressant prescriptions for insomnia. Drug Healthc Patient Saf, pp.27-36, 2011.
DOI : 10.2147/dhps.s21079

URL : https://doi.org/10.2147/dhps.s21079

L. Lannetti, A. Abbouda, C. Fabiani, R. Zito, and M. Campanella, Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report, Journal of Medical Case Reports, vol.44, issue.1, p.199, 2013.
DOI : 10.1167/iovs.01-1277

T. Lazic and V. Falanga, Bioengineered Skin Constructs and Their Use in Wound Healing, Plastic and Reconstructive Surgery, vol.127, issue.1, pp.75-90, 2011.
DOI : 10.1097/PRS.0b013e3182009d9f

J. Lecadet, P. Vidal, B. Baris, N. Vallier, P. Fender et al., Médicaments psychotropes : consommation et pratiques de prescription en France métropolitaine. II. Données et comparaisons régionales, Rev Médicale Assur Mal, vol.34, issue.4, pp.233-281, 2000.

J. Lee, Potential Risks for the Off-Label Use of SSRIs in Premature Ejaculation (CME), The Journal of Sexual Medicine, vol.7, issue.8, pp.2622-2626, 2010.
DOI : 10.1111/j.1743-6109.2010.01945.x

M. Legrain, T. Lecomte, B. Hillemand, R. Nordmann, L. Auquier et al., La consommation des psychotropes en France et dans quelques pays européens. Discussion : Médicaments psychotropes et Société, Bull Académie Natl Médecine, vol.181, issue.6, pp.1073-87, 1997.

C. Lemorton, Conclusion des travaux de la mission d'évaluation et de contrôle des lois de financement de la sécurité sociale sur la prescription, la consommation et la fiscalité des médicaments [Internet] Assemblée nationale, 2008.

C. Lemorton, La prescription, la consommation et la fiscalité des médicaments [Internet], 2008.

T. Lempérière, Historique du développement du valproate dans les troubles bipolaires, EM- Consulte, vol.27, issue.4, p.365, 2001.

D. Leonard, M. Kidson, J. Brown, P. Shannon, and S. Taryan, A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea, Australian & New Zealand Journal of Psychiatry, vol.9, issue.2, pp.115-123, 1975.
DOI : 10.1037/11774-000

M. Leone, D. Amico, D. Frediani, F. Moschiano, F. Grazzi et al., Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo, Neurology, vol.54, issue.6, pp.1382-1387, 2000.
DOI : 10.1212/WNL.54.6.1382

C. Leporini, A. Rende, A. Sorrentino, E. Rizzica, E. Russo et al., Efficacy and Safety of Off-Label Use of Fondaparinux in the Management of Heparin-Induced Thrombocytopenia with Thrombosis in an Elderly Woman, The Journal of Clinical Pharmacology, vol.83, issue.9, pp.999-1002, 2013.
DOI : 10.1002/ajh.21273

D. Leslie, S. Mohamed, and R. Rosenheck, Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System, Psychiatric Services, vol.60, issue.9, pp.1175-81, 2009.
DOI : 10.1176/ps.2009.60.9.1175

H. Lévesque and T. Hanslik, Contraception ??stroprogestative et risque thrombotique??: des faits cliniques aux cons??quences m??diatiques, La Revue de M??decine Interne, vol.34, issue.8, pp.453-458, 2013.
DOI : 10.1016/j.revmed.2013.04.019

O. Lévy-neumand, F. Carniaux, and B. Bonaz, Inhibiteurs de la pompe à protons en médecine générale. Evaluation des pratiques au regard de l'autorisation de mise sur le marché, Disponible sur, 2014.

W. Lipworth, I. Kerridge, M. Little, and R. Day, Evidence and desperation in off-label prescribing: recombinant factor VIIa, BMJ, vol.344, issue.jan16 1, p.7926, 2012.
DOI : 10.1136/bmj.d7926

URL : https://ses.library.usyd.edu.au/bitstream/2123/10788/1/Evidence%20and%20desperation-2012.pdf

A. Logan and L. Goodnough, Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program, pp.153-162, 2010.

A. Logan, Y. V. Stafford, and R. , Off-Label Use of Recombinant Factor VIIa in U.S. Hospitals: Analysis of Hospital Records, Annals of Internal Medicine, vol.154, issue.8, pp.516-538, 2011.
DOI : 10.7326/0003-4819-154-8-201104190-00002

C. Loprinzi, J. Kugler, J. Sloan, J. Mailliard, B. Lavasseur et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial, The Lancet, vol.356, issue.9247, pp.2059-63, 2000.
DOI : 10.1016/S0140-6736(00)03403-6

C. Loprinzi, J. Sloan, E. Perez, S. Quella, P. Stella et al., Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes, Journal of Clinical Oncology, vol.20, issue.6, pp.1578-83, 2002.
DOI : 10.1200/JCO.2002.20.6.1578

M. Loza, C. Brodmerkel, D. Bois, R. Judson, M. Costabel et al., ABSTRACT, Clinical and Vaccine Immunology, vol.18, issue.6, pp.931-940, 2011.
DOI : 10.1128/CVI.00337-10

M. Maglione, A. Maher, J. Hu, Z. Wang, R. Shanman et al., Off-Label Use of Atypical Antipsychotics: An Update [Internet] Rockville (MD): Agency for Healthcare Research and Quality (US), Disponible sur, p.66081, 2011.

A. Maher, M. Maglione, S. Bagley, M. Suttorp, J. Hu et al., Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults, JAMA, vol.306, issue.12, pp.1359-69, 2011.
DOI : 10.1001/jama.2011.1360

A. Maher and G. Theodore, Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics, Journal of Managed Care Pharmacy, vol.18, issue.5 Supp B, pp.1-20, 2012.
DOI : 10.18553/jmcp.2012.18.S5-B.1

S. Maire, P. Lang, G. Kaltenbach, and T. Vogel, Les traitements symptomatiques de la maladie d???Alzheimer??: analyse descriptive des modalit??s de prescription en EHPAD, NPG Neurologie - Psychiatrie - G??riatrie, vol.13, issue.78, pp.355-64, 2013.
DOI : 10.1016/j.npg.2013.08.003

I. Marie, A. Moutot, A. Tharrasse, M. Hellot, S. Robaday et al., Ad??quation aux??recommandations des??prescriptions des??inhibiteurs de??la??pompe ????protons dans??un??service de??m??decine interne, La Revue de M??decine Interne, vol.28, issue.2, pp.86-93, 2007.
DOI : 10.1016/j.revmed.2006.09.030

H. Marret, E. Simon, G. Beucher, M. Dreyfus, A. Gaudineau et al., ??tat des lieux et expertise de l???usage hors AMM du misoprostol en gyn??cologie-obst??trique??: travail du CNGOF (texte court), Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.107-120, 2014.
DOI : 10.1016/j.jgyn.2013.11.005

P. Massin, Rétinopathie diabétique. Ed. scientifiques et médicales, 2000.

J. Mcintyre, S. Conroy, A. Avery, H. Corns, and I. Choonara, Unlicensed and off label prescribing of drugs in general practice, Archives of Disease in Childhood, vol.83, issue.6, pp.498-501, 2000.
DOI : 10.1136/adc.83.6.498

A. Mckean and E. Monasterio, Off-Label Use of Atypical Antipsychotics, CNS Drugs, vol.164, issue.1, pp.383-90, 2012.
DOI : 10.1176/appi.ajp.164.1.174

J. Mcmurray, N. Connor, and C. Ford, Cidofovir Efficacy in Recurrent Respiratory Papillomatosis: A Randomized, Double-Blind, Placebo-Controlled Study, Annals of Otology, Rhinology & Laryngology, vol.117, issue.7, pp.477-83, 2008.
DOI : 10.1001/archotol.129.8.841

. Medscape, DMLA : entre Avastin et Lucentis, seul le prix fait LA différence

M. Fr, Disponible sur: http://www.medscape.fr, p.3600040, 2013.

A. Meretoja, J. Putaala, T. Tatlisumak, S. Atula, V. Artto et al., Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke, Stroke, vol.41, issue.7, pp.1450-1458, 2010.
DOI : 10.1161/STROKEAHA.109.576140

J. Merrill, C. Neuwelt, D. Wallace, J. Shanahan, K. Latinis et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial, Arthritis & Rheumatism, vol.67, issue.1, pp.222-255, 2010.
DOI : 10.4049/jimmunol.174.2.817

F. Moal, M. Moll, and M. Clerc, Indicateur de pertinence des prescriptions d'oméprazole et de voriconazole: un outil d'évaluation des pratiques professionnelles à visée pédagogique, J Pharm Clin, vol.26, issue.3, pp.174-81, 2007.

A. Molinier, B. Acket, R. Bourrel, O. Lavezzi, J. Montastruc et al., Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use

E. Monasterio and A. Mckean, Off-label use of atypical antipsychotic medications in Canterbury, New Zealand, N Z Med J, vol.124, pp.24-33, 1336.

D. Montague, J. Jarow, G. Broderick, R. Dmochowski, J. Heaton et al., AUA GUIDELINE ON THE PHARMACOLOGIC MANAGEMENT OF PREMATURE EJACULATION, The Journal of Urology, vol.172, issue.1, pp.290-294, 2004.
DOI : 10.1097/01.ju.0000132159.61156.ea

J. Morjaria and R. Polosa, Off-label use of omalizumab in non-asthma conditions: new opportunities, Expert Review of Respiratory Medicine, vol.120, issue.3, pp.299-308, 2009.
DOI : 10.1016/j.jaci.2007.09.032

H. Mortazavi, S. Khezri, H. Hosseini, F. Khezri, and M. Vasigh, A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris, Photodermatology, Photoimmunology & Photomedicine, vol.1, issue.3, pp.159-61, 2011.
DOI : 10.1016/S0140-6736(83)92607-7

M. Moudden, J. Labaye, D. Sarret, G. Cazajous, M. Herody et al., Insuffisance r??nale aigu?? secondaire ????la??povidone iod??e: ????propos d'un cas clinique, La Revue de M??decine Interne, vol.28, issue.8, pp.556-564, 2007.
DOI : 10.1016/j.revmed.2007.04.006

E. Murray and M. Perry, Off-label use of rituximab in systemic lupus erythematosus: a systematic review, Clinical Rheumatology, vol.24, issue.Suppl3, pp.707-723, 2010.
DOI : 10.4049/jimmunol.174.2.817

N. Nhamcs, Ambulatory Health Care Data [Internet]. Cent. Dis. Control Prev, 2014.

P. Newton, P. Davidson, P. Macdonald, R. Ollerton, and H. Krum, Nebulized Furosemide for the Management of Dyspnea: Does the Evidence Support Its Use?, Journal of Pain and Symptom Management, vol.36, issue.4, pp.424-465, 2008.
DOI : 10.1016/j.jpainsymman.2007.10.017

P. Newton, P. Davidson, and C. Sanderson, Improving Palliative Care through Clinical Trials (ImPaCCT) group. An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide, BMC Palliat Care, vol.11, issue.6, 2012.

S. Nickle, N. Peterson, and M. Peterson, Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin, J Clin Aesthet Dermatol, vol.7, issue.4, pp.22-34, 2014.

M. Onder, C. Salavastru, and K. Fritz, Off-label use of infliximab, Der Hautarzt, vol.86, issue.10, pp.757-61, 2013.
DOI : 10.1136/bjo.86.5.521

M. Orum, O. Hilberg, S. Krag, and E. Bendstrup, Beneficial effect of infliximab on refractory sarcoidosis, Dan Med J, vol.59, issue.12, p.4535, 2012.

V. Osborne, D. Layton, C. Fogg, M. Shukri, and S. Shakir, Utilization of fentanyl buccal tablets in England: Exploring off-label use reported in a cohort study, European Journal of Pain, vol.29, issue.4, pp.506-518, 2013.
DOI : 10.1016/j.clinthera.2007.04.007

F. Paille, Mésusage de l'alcool et nouveaux traitements médicamenteux, Rev Prat, vol.61, issue.10, pp.1386-91, 2011.

K. Pandya, G. Morrow, J. Roscoe, J. Hickok, H. Zhao et al., Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial, The Lancet, vol.366, issue.9488, pp.818-842, 2005.
DOI : 10.1016/S0140-6736(05)67215-7

A. Parodi, F. Drago, S. Paolino, E. Cozzani, and R. Gallo, Prise en charge th??rapeutique de la rosac??e, Annales de Dermatologie et de V??n??r??ologie, vol.138, pp.158-62, 2011.
DOI : 10.1016/S0151-9638(11)70082-5

G. Pasqualetti, S. Ricci, A. Dardano, M. Ferdeghini, D. Tacca et al., The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature, Mini-Reviews in Medicinal Chemistry, vol.11, issue.9, pp.746-52, 2011.
DOI : 10.2174/138955711796355249

R. Penaloza, U. Sarkar, D. Claman, and T. Omachi, Trends in On-label and Off-label Modafinil Use in a Nationally Representative Sample, JAMA Internal Medicine, vol.173, issue.8, pp.704-710, 2013.
DOI : 10.1001/jamainternmed.2013.2807

D. Pfister, Off-Label Use of Oncology Drugs: The Need for More Data and Then Some, Journal of Clinical Oncology, vol.30, issue.6, pp.584-590, 2012.
DOI : 10.1200/JCO.2011.38.5567

D. Picard, P. Carvalho, C. Bonnavia, L. Louin, V. Josset et al., Assessment off-label prescribing in Dermatology], Ann Dermatol Vénéréologie, vol.130, issue.5, pp.507-517, 2003.

U. Pike, R. , and M. B. Usa-20894, Oral erythromycin and symptomatic relief of gastroparesis: a systematic review, PubMed Health, vol.98, issue.2, pp.259-63, 2003.

S. Poole and M. Dooley, Off-label prescribing in oncology Support Care Cancer Off J Multinatl Assoc Support Care Cancer, pp.302-307, 2004.

P. Pouchoulin, É. Dugaret, and B. Burucoa, Voie sous-cutanée en situation palliative: entre recommandations et pratiques. Enquête auprès des unités de soins palliatifs françaises en 2011. Médecine Palliat Soins Support-Accompagnement-Éthique, pp.9-16, 2013.
DOI : 10.1016/j.medpal.2013.02.007

R. Rabello-fonseca, D. Azulay, R. Luiz, C. Mandarim-de-lacerda, T. Cuzzi et al., Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication, Journal of the European Academy of Dermatology and Venereology, vol.10, issue.Suppl. 2, pp.115-138, 2009.
DOI : 10.1590/S0365-05962003000300002

M. Ramos-casals, F. García-hernández, E. De-ramón, J. Callejas, A. Martínez-berriotxoa et al., Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases, Clin Exp Rheumatol. août, vol.28, issue.4, pp.468-76, 2010.

M. Ramos-casals, M. Soto, M. Cuadrado, and M. Khamashta, Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases, Lupus, vol.58, issue.9, pp.767-76, 2009.
DOI : 10.1177/0961203308090033

D. Van-rappard, J. Limpens, and J. Mekkes, The off-label treatment of severe hidradenitis suppurativa with TNF-?? inhibitors: a systematic review, Journal of Dermatological Treatment, vol.57, issue.2, pp.392-404, 2013.
DOI : 10.1016/j.jaad.2007.07.032

G. Remington and M. Hahn, Off-label antipsychotic use and tardive dyskinesia in at-risk popu lations: new drugs with old side effects, Journal of Psychiatry & Neuroscience, vol.39, issue.1, pp.1-2, 2014.
DOI : 10.1503/jpn.130222

P. Rewri, S. Balekudaru, J. Shah, R. George, and V. Lingam, Safety and Efficacy of Using Off-Label Bevacizumab Versus Mitomycin C to Prevent Bleb Failure in a Single Site Phacotrabeculectomy by a Randomized Controlled Clinical Trial, Journal of Glaucoma, vol.22, issue.3, p.266, 2013.
DOI : 10.1097/IJG.0b013e3182877d04

L. Rigal, C. Alexandre-dubroeucq, D. Beaurepaire, and R. , Is high-dose of baclofen a safe and effective treatment of alcoholism? A 1-year retrospective study, Fund Clin Pharmacol, vol.25, issue.A346, 2011.

B. Roehr, Abbott pays $1.6bn for promoting off label use of valproic acid, BMJ, vol.344, issue.may11 1, p.3343, 2012.
DOI : 10.1136/bmj.e3343

F. Roila, E. Ballatori, R. Labianca, D. Braud, F. Borgonovo et al., Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey, Tumori Journal, vol.12, issue.6, pp.647-51, 2009.
DOI : 10.1007/s00520-004-0593-6

M. Rosenbluth and M. Sinyor, Off-label use of atypical antipsychotics in personality disorders, Expert Opinion on Pharmacotherapy, vol.20, issue.1, pp.1575-85, 2012.
DOI : 10.1002/pds.2082

P. Rosenfeld and K. Goodman, When Is Off-Label Drug Use in the Patient's Best Interest?, American Journal of Ophthalmology, vol.147, issue.5, pp.761-764, 2009.
DOI : 10.1016/j.ajo.2009.01.011

. Rothenberg, Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas, Technol Eval Cent Assess Program Exec Summ, vol.24, issue.4, pp.1-3, 2009.

E. Russell, F. Luk, S. Manocha, T. Ho, O. Connor et al., Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy, Seminars in Arthritis and Rheumatism, vol.43, issue.1, pp.119-143, 2013.
DOI : 10.1016/j.semarthrit.2012.10.008

S. Al-ruzzeh and J. Navia, The ???Off-Label??? Role of Recombinant Factor VIIa in Surgery: Is the Problem Deficient Evidence or Defective Concept?, Journal of the American College of Surgeons, vol.209, issue.5, pp.659-67, 2009.
DOI : 10.1016/j.jamcollsurg.2009.07.018

S. Al-ruzzeh and J. Navia, Caution with the published database reviews analyzing the off-label use of recombinant activated factor VII (rFVIIa) in cardiac surgery, Transfusion and Apheresis Science, vol.43, issue.2, pp.245-251, 2010.
DOI : 10.1016/j.transci.2010.07.014

C. Salavastru, K. Fritz, and G. Tiplica, Spironolactone in dermatological treatment, Der Hautarzt, vol.68, issue.10, pp.762-769, 2013.
DOI : 10.1016/j.jaad.2012.09.034

D. Sanchez-cano, J. Callejas-rubio, R. Ruiz-villaverde, R. Rios-fernandez, and N. Ortego-centeno, Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Beh??et???s Disease, Sarcoidosis, and Noninfectious Uveitis, Mediators of Inflammation, vol.63, issue.4, p.286857, 2013.
DOI : 10.1016/j.semarthrit.2011.05.005

S. Gopal and K. , Off with the label and on the Avastin bandwagon: Why now and how far?, Indian Journal of Ophthalmology, vol.57, issue.4, pp.253-259, 2009.
DOI : 10.4103/0301-4738.53048

F. Sarullo, G. Fazio, D. Puccio, S. Fasullo, S. Paterna et al., Impact of ??????Off-Label?????? Use of Ivabradine on Exercise Capacity, Gas Exchange, Functional Class, Quality of Life, and Neurohormonal Modulation in Patients With Ischemic Chronic Heart Failure, Journal of Cardiovascular Pharmacology and Therapeutics, vol.21, issue.12, pp.349-55, 2010.
DOI : 10.1016/0735-1097(94)90174-0

K. Scheller and C. Scheller, Nimodipine promotes regeneration of peripheral facial nerve function after traumatic injury following maxillofacial surgery: an off label pilot-study. J Cranio- Maxillo-fac Surg Off Publ Eur Assoc Cranio-Maxillo-fac Surg, pp.427-461, 2012.

M. Schindewolf, J. Scheuermann, H. Kroll, I. Marzi, R. Kaufmann et al., Application, tolerance and safety of fondaparinux therapy in a German hospital: A prospective single-centre experience, Thrombosis Research, vol.129, issue.1, pp.17-21, 2012.
DOI : 10.1016/j.thromres.2011.06.008

C. Schmucker, C. Ehlken, H. Agostini, G. Antes, G. Ruecker et al., A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard, PLoS ONE, vol.7, issue.8, p.42701, 2012.
DOI : 10.1371/journal.pone.0042701.s001

M. Schram, R. Borgonjen, C. Bik, J. Van-der-schroeff, J. Van-everdingen et al., Off-label Use of Azathioprine in Dermatology, Archives of Dermatology, vol.147, issue.4, pp.474-88, 2011.
DOI : 10.1001/archdermatol.2011.79

T. Schwartz, N. Nihalani, S. Virk, S. Jindal, A. Costello et al., A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia, Int J Psychiatr Nurs Res, vol.10, issue.1, pp.1146-50, 2004.

F. Seite, A. Delelis-fanien, S. Valero, C. Pradère, J. Poupet et al., Prescription des inhibiteurs de la pompe ?? protons en g??riatrie, La Revue de M??decine Interne, vol.29, issue.S3, p.327, 2008.
DOI : 10.1016/j.revmed.2008.10.109

M. Selim, Traitement de l'oedème maculaire diabétique par injection intravitréenne d'acétonide de triamcinolone : conséquences fonctionnelles et anatomiques. EM- Consulte, pp.32-40, 2007.

L. Sentilhes, P. Jeanneteau, E. Parot-schinkel, M. Mercier, and P. Descamps, Inhibition de la lactation : fin de la bromocriptine, longue vie à la cabergoline ? Gynécologie Obstétrique Fertil, pp.197-206, 2014.
DOI : 10.1016/j.gyobfe.2013.12.007

V. Serebruany, N. Kipshidze, I. Pershukov, W. Kuliczkowski, J. Carnes et al., Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel, American Journal of Therapeutics, vol.21, issue.6, pp.441-553, 2013.
DOI : 10.1097/MJT.0b013e31828fdb1c

E. Shigeto, The current status of fluoroquinolones and other off-label drug use for tuberculosis in Japan, Kekkaku, vol.85, issue.10, pp.757-60, 2010.

H. Al-shobaili and S. Al-khenaizan, Childhood Generalized Pustular Psoriasis: Successful Treatment with Isotretinoin, Pediatric Dermatology, vol.19, issue.5, pp.563-567, 2007.
DOI : 10.1001/archderm.121.10.1297

J. Shornick, N. Formica, and A. Parke, Isotretinoin for refractory lupus erythematosus, Journal of the American Academy of Dermatology, vol.24, issue.1, pp.49-52, 1991.
DOI : 10.1016/0190-9622(91)70008-P

C. Shriqui, Polypharmacie en psychiatrie: nouvelles tendances, vieilles mø eurs, Inf Psychiatr, vol.81, issue.2, pp.101-110, 2005.

C. Shriqui, Réflexion sur l'utilisation grandissante hors AMM des psychotropes, Inf Psychiatr, vol.81, issue.2, pp.120-124, 2005.

E. Simon and X. Fritel, L???usage hors AMM du misoprostol en gyn??cologie-obst??trique??: m??thodes et organisation, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.103-109, 2014.
DOI : 10.1016/j.jgyn.2013.11.004

E. Simon and H. Marret, L???usage hors AMM du misoprostol en gyn??cologie-obst??trique??: introduction, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2, pp.87-102, 2014.
DOI : 10.1016/j.jgyn.2013.11.003

A. Siniscalchi, L. Gallelli, G. Tolotta, D. Loiacono, D. Sarro et al., Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis, Clinical Therapeutics, vol.32, issue.12, pp.2030-2034, 2010.
DOI : 10.1016/j.clinthera.2010.10.012

M. «. Sirakov, Off label » use of some medicinal products. Part II. « Off label » use of misoprostol, Akush Ginekol Sofiia, vol.51, issue.3, pp.50-54, 2012.

R. Sobel, D. Wu, K. Hester, and K. Anda, Tissue plasminogen activator for transient ischemic attack: the case for ???off-label??? use of thrombolytics, The American Journal of Emergency Medicine, vol.32, issue.3, pp.277-286, 2014.
DOI : 10.1016/j.ajem.2013.10.046

R. Spaide, K. Laud, H. Fine, J. Klancnik, . Jr et al., Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration, Retina Phila Pa. avr, vol.26, issue.4, pp.383-90, 2006.

E. Stagaki, W. Mountford, D. Lackland, and M. Judson, The Treatment of Lupus Pernio, Chest, vol.135, issue.2, pp.468-76, 2009.
DOI : 10.1378/chest.08-1347

V. Stearns, K. Beebe, M. Iyengar, and E. Dube, Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes, JAMA, vol.289, issue.21, pp.2827-2861, 2003.
DOI : 10.1001/jama.289.21.2827

V. Stearns, R. Slack, N. Greep, R. Henry-tilman, M. Osborne et al., Paroxetine Is an Effective Treatment for Hot Flashes: Results From a Prospective Randomized Clinical Trial, Journal of Clinical Oncology, vol.23, issue.28
DOI : 10.1200/JCO.2005.10.081

T. Steiner, R. Hering, E. Couturier, P. Davies, and T. Whitmarsh, Double-Blind Placebo-Controlled Trial of Lithium in Episodic Cluster Headache, Cephalalgia, vol.88, issue.6, pp.673-678, 1997.
DOI : 10.1016/0197-2456(93)90013-4

M. Stève-dumont, M. Chemin, O. Taouss, and L. Vergely, ??valuation des pratiques de prescription du rituximab en rhumatologie, Le Pharmacien Hospitalier et Clinicien, vol.47, issue.4, pp.238-281, 2012.
DOI : 10.1016/j.phclin.2012.05.004

C. Tanguy-goarin and V. Cogulet, Administration des m??dicaments par voie sous-cutan??e en soins palliatifs, Th??rapie, vol.65, issue.6, pp.525-556, 2010.
DOI : 10.2515/therapie/2010066

M. Tartaglia, B. Hu, K. Mehta, J. Neuhaus, K. Yaffe et al., Demographic and Neuropsychiatric Factors Associated With Off-label Medication Use in Frontotemporal Dementia and Alzheimer???s Disease, Alzheimer Disease & Associated Disorders, vol.28, issue.2, pp.182-191, 2013.
DOI : 10.1097/WAD.0b013e3182a7159d

S. Telimaa, J. Puolakka, L. Rönnberg, and A. Kauppila, Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis, Gynecological Endocrinology, vol.36, issue.1
DOI : 10.1016/S0015-0282(16)45611-6

P. Theodossiadis, V. Liarakos, P. Sfikakis, I. Vergados, and G. Theodossiadis, Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular Degeneration, American Journal of Ophthalmology, vol.147, issue.5, pp.825-855, 2009.
DOI : 10.1016/j.ajo.2008.12.004

R. Tjon-pian-gi, A. Dietz, V. Djukic, H. Eckel, G. Friedrich et al., Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®) Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol -Head Neck Surg, févr, vol.269, issue.2, pp.361-363, 2012.

K. Toulis, T. Tzellos, D. Kouvelas, and D. Goulis, Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: A systematic review and meta-analysis, Clinical Therapeutics, vol.31, issue.2, pp.221-256, 2009.
DOI : 10.1016/j.clinthera.2009.02.006

M. Uslu, E. ?avk, G. Karaman, and N. ?endur, Rosacea Treatment with Intermediate-dose Isotretinoin: Follow-up with Erythema and Sebum Measurements, Acta Dermato Venereologica, vol.92, issue.1, pp.73-80, 2012.
DOI : 10.2340/00015555-1204

URL : https://www.medicaljournals.se/acta/content_files/download.php?doi=10.2340/00015555-1204

S. Vaishnavi, S. Alamy, W. Zhang, K. Connor, and J. Davidson, Quetiapine as monotherapy for social anxiety disorder: A placebo-controlled study, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.31, issue.7, pp.1464-1473, 2007.
DOI : 10.1016/j.pnpbp.2007.06.027

S. Vedula, L. Bero, R. Scherer, and K. Dickersin, Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use, New England Journal of Medicine, vol.361, issue.20, pp.1963-71, 2009.
DOI : 10.1056/NEJMsa0906126

S. Vedula, T. Li, and K. Dickersin, Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin, PLoS Medicine, vol.367, issue.1, p.1001378, 2013.
DOI : 10.1371/journal.pmed.1001378.s001

G. Vena, C. Coviello, and G. Angelini, Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus, G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr, vol.124, issue.6, pp.311-316, 1989.

P. Vercellini, D. Giorgi, O. Oldani, S. Cortesi, I. Panazza et al., Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-lowdose danazol for long-term treatment of pelvic pain associated with endometriosis

P. Vestergaard, P. Baastrup, and H. Petersson, Lithium treatment of Huntington's chorea., Acta Psychiatrica Scandinavica, vol.29, issue.3, pp.183-191, 1977.
DOI : 10.1016/S0140-6736(74)93130-4

M. Villiet, L. Giraudon, C. Combescure, and S. Hansel-esteller, Bon usage des inhibiteurs de la pompe à protons: étude observationnelle des prescriptions en milieu hospitalier, J Pharm Clin, vol.28, issue.3, pp.135-175, 2009.

J. Walsh, M. Erman, C. Erwin, A. Jamieson, M. Mahowald et al., Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia, Human Psychopharmacology: Clinical and Experimental, vol.44, issue.3, pp.191-199, 1998.
DOI : 10.1097/00004714-199006000-00005

S. Walton, W. Galanter, H. Rosencranz, D. Meltzer, R. Stafford et al., A trial of inpatient indication based prescribing during computerized order entry with medications commonly used off-label, Applied Clinical Informatics, vol.2, issue.1, pp.94-103, 2011.
DOI : 10.4338/ACI-2010-11-RA-0072

V. Yank, C. Tuohy, A. Logan, D. Bravata, K. Staudenmayer et al., Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications, Annals of Internal Medicine, vol.154, issue.8, pp.529-569, 2011.
DOI : 10.7326/0003-4819-154-8-201104190-00004

C. Yeo, M. Barry, P. Sauter, S. Sostre, K. Lillemoe et al., Erythromycin Accelerates Gastric Emptying After Pancreaticoduodenectomy, Annals of Surgery, vol.218, issue.3, pp.229-267, 1993.
DOI : 10.1097/00000658-199309000-00002

F. Ziemssen, S. Grisanti, K. Bartz-schmidt, and M. Spitzer, Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration, Drugs & Aging, vol.86, issue.4, pp.295-320, 2009.
DOI : 10.1155/2008/707864